Our data indicate that the flow-based assessment of MHC-I expression in pretreatment melanoma biopsies may aid in first-line immunotherapy selection, by identifying patients with MHC-I-low melanoma that may preferentially benefit from the more toxic combination (anti-PD-1 plus anti-CTLA-4) immunotherapy. The gene discussed is PDCD1; the disease is melanoma.